Pacira Biosciences Inc (PCRX) stock is up 52.34% over the last 12 months, and the average rating from Wall Street analysts is a Buy. InvestorsObserver’s proprietary ranking system, gives PCRX stock a score of 82 out of a possible 100.
That rank is primarily influenced by a short-term technical score of 98. PCRX's rank also includes a long-term technical score of 77. The fundamental score for PCRX is 71. In addition to the average rating from Wall Street analysts, PCRX stock has a mean target price of 65.727. This means analysts expect the stock to gain 13.24% over the next 12 months.
What's Happening with PCRX Stock Today
Pacira Biosciences Inc (PCRX) stock is down -0.22% while the S&P 500 is down -0.66% as of 1:13 PM on Wednesday, Oct 14. PCRX is down -$0.13 from the previous closing price of $58.17 on volume of 161,141 shares. Over the past year the S&P 500 has risen 16.47% while PCRX is up 52.34%. PCRX lost -$0.24 per share in the over the last 12 months.
Click Here to get the full Stock Score Report on Pacira Biosciences Inc (PCRX) Stock.
